Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS207 + JS007
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JS207 + JS007 is an investigational combination therapy developed by Junshi Biosciences for the treatment of advanced malignancies, primarily advanced hepatocellular carcinoma (HCC). The combination consists of two active biologic components: JS207, a recombinant humanized bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), and JS007, a recombinant humanized IgG1 monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). By simultaneously blocking the PD-1/PD-L1 pathway, inhibiting VEGF-A-mediated angiogenesis, and blocking CTLA-4-mediated inhibitory signaling on T cells, the combination aims to synergistically enhance T-cell activation and promote robust anti-tumor immune responses in the tumor microenvironment. The combination is currently being evaluated in Phase III clinical trials as a first-line treatment for advanced (unresectable or metastatic) hepatocellular carcinoma.
- Other names
- JS207 combined with JS007JS-207 combined with JS007JS 207 combined with JS007JS207 in combination with JS007JS-207 in combination with JS007JS 207 in combination with JS007JS207 plus JS007JS-207 plus JS007JS 207 plus JS007
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on JS207 + JS007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS207 + JS007.